The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | The need for enhanced biomarkers in metastatic colorectal cancer
Marco Germani, MD, FRCP, University of Pisa, Pisa, Italy, comments on the limitations of RAS/BRAF profiling and next-generation sequencing (NGS) in capturing the complexity of metastatic colorectal cancer (mCRC). Patients are expected to have a favorable prognosis often experience poor outcomes or rapid resistance to first-line therapies, highlighting the need for improved biomarkers. While compressed genome expression profiling may help refine understanding in these patients, established biomarkers like BRAF still play a crucial role. Thus, mRNA profiling is important to better predict responses and outcomes in this heterogeneous disease. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
